Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Deals

Lion TCR Secures RMB 300 Million in Series B2 Financing to Advance Clinical Studies and Facility Construction

Fineline Cube Jun 27, 2023

Singapore-based clinical-stage biotechnology company Lion TCR has announced the successful completion of its Series B2...

Company Drug

LianBio’s Mavacamten Receives Priority Review Status from China’s CDE for oHCM Treatment

Fineline Cube Jun 27, 2023

The Center for Drug Evaluation (CDE) has indicated on its website that China-based biotech firm...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for JMT203 Cancer Cachexia Clinical Study

Fineline Cube Jun 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Policy / Regulatory

NMPA Releases 69th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jun 27, 2023

The National Medical Products Administration (NMPA) has released the 69th batch of reference drugs for...

Company Deals

BDgene Technology Secures Over RMB 200 Million in Series B Financing Led by Lapam Capital

Fineline Cube Jun 27, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has successfully raised over RMB 200 million...

Company Deals

WuXi Biologics Partners with Pharmadule Morimatsu AB for CRDMO Expansion in Singapore

Fineline Cube Jun 27, 2023

China-based WuXi Biologics (HKG: 2269) has announced a strategic partnership with Sweden-headquartered Pharmadule Morimatsu AB...

Company Drug

CStone Pharmaceuticals’ Gavreto Approved for First-Line RET Fusion-Positive NSCLC Treatment in China

Fineline Cube Jun 27, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) of...

Company Drug

CSPC Pharmaceutical’s Biosimilar Omalizumab Accepted for Review by China’s NMPA

Fineline Cube Jun 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that the National Medical Products Administration...

Company Drug

Henlius Biotech’s HLX13 Biosimilar Gets NMPA Approval for Liver Cancer Clinical Trial

Fineline Cube Jun 27, 2023

Shanghai Henlius Biotech, Inc (HKG: 2696) has announced receiving clinical trial approval from the National...

Company Drug

Chia Tai Tianqing Launches First Batch of F-627 for Neutropenia Treatment in China

Fineline Cube Jun 27, 2023

China-based Chia Tai Tianqing has announced the first batch prescriptions in China for its efbemalenograstim...

Company Drug

Jiangsu Kanion Pharmaceutical Gets FDA Approval for KYS202002A Clinical Study in Multiple Myeloma

Fineline Cube Jun 27, 2023

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving the green light from...

Company Deals

Mega Lifesciences Secures Exclusive Rights for Bio-Thera’s Bevacizumab Biosimilar in Indonesia

Fineline Cube Jun 27, 2023

Thailand-based Mega Lifesciences (BKK: MEGA) has announced an in-licensing agreement with China-based Bio-Thera Solutions (SHA:...

Company Drug

Jiangsu Hengrui’s Dalpiciclib Approved for Initial Therapy in HR+, HER2- Breast Cancer

Fineline Cube Jun 27, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma

Fineline Cube Jun 27, 2023

China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co.,...

Company Drug

Ascletis Pharma’s ASC42 Showcased in Combination Therapy for Chronic Hepatitis B at EASL 2023

Fineline Cube Jun 26, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) announced the poster presentation of ASC42, a novel farnesoid...

Company Deals Policy / Regulatory

Sinopharm Expands Partnership with Guizhou Government to Boost Health Industry

Fineline Cube Jun 26, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strengthened partnership with the...

Company Deals

Coherent Biopharma and C-Ray Therapeutics Partner to Advance Peptide-Drug Conjugate Development

Fineline Cube Jun 26, 2023

China-based Coherent Biopharma and C-Ray Therapeutics have announced a strategic partnership to delve into the...

Company Drug

CANbridge Pharmaceuticals Reports Positive Phase Ib Results for Omoprubart in PNH Treatment

Fineline Cube Jun 26, 2023

China-based rare disease firm CANbridge Pharmaceuticals Inc., (HKG: 1228) has published the preliminary results of...

Company Medical Device

Sino Medical Sciences Technology Secures FDA Thailand Approval for NC Rockstar Balloon Catheter

Fineline Cube Jun 26, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received market...

Company Drug

Haisco Pharmaceutical’s HSK31679 Receives Clinical Trial Approval for NASH Treatment

Fineline Cube Jun 26, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its in-house developed Category...

Posts pagination

1 … 556 557 558 … 711

Recent updates

  • Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
  • WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.